Deenan Pillay

Q: What Schools Are Affiliated With Deenan Pillay

Deenan Pillay is affiliated with the following schools: Imperial College London, University College London, University of Oxford, University of KwaZulu-Natal, University of Birmingham

Deenan Pillay's AcademicInfluence.com Rankings

Deenan Pillay

Biology

#9472

World Rank

#12683

Historical Rank

Virology

#219

World Rank

#226

Historical Rank

Microbiology

#506

World Rank

#567

Historical Rank

biology Degrees

Download Badge

Biology

Deenan Pillay's Degrees

Bachelors Biomedical Science University of Oxford

Why Is Deenan Pillay Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Deenan Pillay's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Update of the Drug Resistance Mutations in HIV-1. (2008) (2026)
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update (2009) (905)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2008) (569)
Digital technologies in the public-health response to COVID-19 (2020) (539)
Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study (2020) (367)
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis (2012) (365)
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. (2011) (361)
2011 update of the drug resistance mutations in HIV-1. (2011) (339)
Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration (2005) (337)
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance (2007) (335)
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study (2021) (313)
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. (2009) (266)
Update of the drug resistance mutations in HIV-1: Fall 2005. (2005) (254)
Update of the drug resistance mutations in HIV-1: Fall 2006. (2006) (250)
Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. (2005) (246)
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis (2017) (239)
Update of the drug resistance mutations in HIV-1: March 2013. (2013) (237)
Update of the drug resistance mutations in HIV-1: December 2010. (2010) (234)
Update of the drug resistance mutations in HIV-1: December 2009. (2008) (231)
HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy (2004) (222)
Taking connected mobile-health diagnostics of infectious diseases to the field (2019) (217)
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. (2008) (210)
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. (2000) (207)
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. (2017) (195)
Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion (2009) (195)
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study (2005) (192)
Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model (2008) (192)
Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study (2020) (191)
Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing (2004) (185)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting (2001) (184)
Update of the drug resistance mutations in HIV-1: 2007. (2007) (183)
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections (2005) (182)
Emergence and Evolution of Enfuvirtide Resistance following Long-Term Therapy Involves Heptad Repeat 2 Mutations within gp41 (2005) (179)
2017 Update of the Drug Resistance Mutations in HIV-1. (2016) (177)
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration (2009) (174)
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance (2009) (169)
Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom (2001) (168)
Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus (2013) (165)
AN OPEN-LABEL STUDY OF TENOFOVIR IN HIV-1 AND HEPATITIS B VIRUS CO-INFECTED INDIVIDUALS (2002) (161)
Update of the Drug Resistance Mutations in HIV-1: 2005. (2005) (160)
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice (2005) (158)
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. (2009) (156)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016) (155)
Disease-associated XMRV sequences are consistent with laboratory contamination (2010) (154)
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach (2010) (153)
Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency (2020) (153)
HIV and hepatitis C coinfection within the CAESAR study (2004) (148)
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. (1999) (147)
2014 Update of the drug resistance mutations in HIV-1. (2014) (146)
Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel (2018) (146)
Update of the drug resistance mutations in HIV-1: Spring 2008. (2008) (142)
2015 Update of the Drug Resistance Mutations in HIV-1. (2015) (140)
Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection (1992) (132)
Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient (2000) (131)
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa (2006) (130)
Long-Term Persistence of Primary Genotypic Resistance After HIV-1 Seroconversion (2004) (129)
Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site (2018) (127)
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man (2004) (122)
Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes (2012) (120)
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy (2006) (118)
Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa (2015) (117)
Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication (2008) (113)
Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. (2000) (112)
PROVISION OF PROGNOSTIC INFORMATION IN IMMUNOCOMPROMISED PATIENTS BY ROUTINE APPLICATION OF THE POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS (1993) (110)
Update of the drug resistance mutations in HIV-1: 2004. (2004) (110)
Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease (1999) (108)
Drug resistance mutations in HIV-1. (2003) (108)
Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent (2006) (108)
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count (2007) (106)
Demonstration of Sustained Drug-Resistant Human Immunodeficiency Virus Type 1 Lineages Circulating among Treatment-Naïve Individuals (2009) (106)
Incidence and impact of resistance against approved antiretroviral drugs (2000) (106)
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. (2002) (104)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. (2001) (101)
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. (2013) (99)
Persistence of HIV-1 Transmitted Drug Resistance Mutations (2013) (98)
Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure (2014) (98)
Persistence of HIV-1 Transmitted Drug Resistance Mutations (2013) (98)
HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era (2011) (98)
Transmission of HIV-1 drug resistance. (2004) (96)
Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? (2000) (94)
Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings (2011) (94)
Phylogenetic Surveillance of Viral Genetic Diversity and the Evolving Molecular Epidemiology of Human Immunodeficiency Virus Type 1 (2007) (94)
Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United Kingdom (2001) (91)
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis (2002) (91)
Prevalence of Transmitted HIV-1 Drug Resistance and the Role of Resistance Algorithms: Data From Seroconverters in the CASCADE Collaboration From 1987 to 2003 (2005) (88)
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa (2017) (87)
Phylogenetic Studies of Transmission Dynamics in Generalized HIV Epidemics: An Essential Tool Where the Burden is Greatest? (2014) (83)
Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic (2020) (82)
Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. (2000) (80)
Gag Determinants of Fitness and Drug Susceptibility in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 (2009) (80)
Asymptomatic urethritis and detection of HIV-1 RNA in seminal plasma. (1999) (77)
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men (2000) (75)
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study (2018) (75)
Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up (2001) (75)
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays (2010) (74)
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. (2001) (74)
Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir (2001) (73)
Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells (2013) (73)
Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis (2013) (72)
Comparative assessment of five trials of universal HIV testing and treatment in sub‐Saharan Africa (2018) (72)
Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns (2004) (70)
Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. (2005) (69)
Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe (2004) (69)
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study (2007) (69)
Use of Real-Time PCR and Fluorimetry To Detect Lamivudine Resistance-Associated Mutations in Hepatitis B Virus (1999) (69)
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom (2007) (68)
Recent trends and patterns in HIV‐1 transmitted drug resistance in the United Kingdom (2016) (68)
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions (2014) (68)
Time and Money: The True Costs of Health Care Utilization for Patients Receiving “Free” HIV/Tuberculosis Care and Treatment in Rural KwaZulu-Natal (2015) (67)
SOLID ORGAN TRANSPLANTATION IN PATIENTS WITH HIV INFECTION (2001) (67)
Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. (2004) (67)
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children (2007) (66)
Semen characteristics in HIV-1 positive men and the effect of semen washing. (1997) (65)
From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. (2017) (65)
Phylogenetic insights into regional HIV transmission (2012) (65)
Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase (2008) (64)
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. (2010) (64)
Constructing the cascade of HIV care: methods for measurement (2016) (64)
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. (2003) (64)
CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK (2009) (63)
Direct visualization and quantitation of cytomegalovirus-specific CD8+ cytotoxic T-lymphocytes in liver transplant patients. (2000) (63)
Analysis of Hepatitis B Virus Quasispecies Changes during Emergence and Reversion of Lamivudine Resistance in Liver Transplantation (1999) (62)
Parvovirus B19 outbreak in a children's ward (1992) (61)
Poor penetration of the male genital tract by HIV-1 protease inhibitors. (1999) (61)
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study (2017) (60)
Investigation of vesicular rashes for HSV and VZV by PCR (1998) (59)
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. (2010) (59)
THE PROGNOSTIC SIGNIFICANCE OF POSITIVE CMV CULTURES DURING SURVEILLANCE OF RENAL TRANSPLANT RECIPIENTS (1993) (59)
Persistently high incidence of HIV and poor service uptake in adolescent girls and young women in rural KwaZulu-Natal, South Africa prior to DREAMS (2018) (59)
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy (2008) (58)
Prevalence of long‐term BK and JC excretion in HIV‐infected adults and lack of correlation with serological markers (1999) (57)
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase (2004) (57)
Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. (2000) (57)
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study * (2010) (56)
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study (2017) (55)
Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community (2017) (55)
A clinico-pathological audit of opportunistic viral infections in HIV-infected patients. (1993) (54)
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study (2012) (54)
Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation (2014) (54)
Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa (2016) (54)
Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa (2017) (53)
The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom (2010) (53)
The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes (2009) (52)
PANGEA-HIV: phylogenetics for generalised epidemics in Africa. (2015) (52)
Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study (2000) (51)
The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection (2014) (51)
Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. (2002) (51)
Diagnosis of primary human herpesvirus 6 and 7 infections in febrile infants by polymerase chain reaction (1997) (51)
Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. (2008) (50)
JC virus associated meningoencephalitis in an immunocompetent girl. (1992) (50)
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study (2016) (49)
Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial (2020) (49)
Cytomegalovirus Infection and Risk of AIDS in Human Immunodeficiency Virus-Infected Hemophilia Patients (1993) (49)
British HIV Association guidelines for antiretroviral treatment of HIV‐2‐positive individuals 2010 (2010) (48)
Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease (2011) (48)
Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study) (2010) (48)
HIV in the UK 1980–2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy (2007) (48)
Use of Whole-Genome Sequencing in the Investigation of a Nosocomial Influenza Virus Outbreak (2018) (47)
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. (2002) (46)
A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products. (1998) (46)
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. (2010) (46)
Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis (2019) (46)
Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load (2006) (46)
Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors (2014) (45)
High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy (2013) (44)
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. (2009) (44)
Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial (2018) (44)
When and how to use maraviroc in HIV-infected patients (2009) (44)
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. (2004) (44)
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. (2014) (43)
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. (2007) (43)
Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis (2019) (42)
Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study (2012) (42)
Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. (2003) (42)
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. (2010) (42)
Optimal use of maraviroc in clinical practice. (2008) (42)
The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy. (2006) (41)
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy (2009) (41)
Improving the care of patients with genital herpes (2000) (41)
Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda (2020) (41)
Estimating excess 1- year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults (2020) (41)
Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. (2015) (41)
Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication Capacity (2010) (40)
Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study (2021) (40)
Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study (2021) (40)
The causal effect of childhood measles vaccination on educational attainment: A mother fixed-effects study in rural South Africa (2015) (39)
Isolation of viruses from stools in stem cell transplant recipients: a prospective surveillance study (2000) (39)
Towards an ultra-rapid smartphone- connected test for infectious diseases (2017) (38)
Testing for HIV: concise guidance. (2009) (38)
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. (2010) (37)
Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study (2011) (37)
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. (2001) (37)
Long‐term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study (2011) (37)
The Emergence and Epidemiology of Resistance in the Nucleoside-Experienced HIV-Infected Population (2000) (37)
HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004 (2008) (36)
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity (2006) (36)
Lessons from countries implementing find, test, trace, isolation and support policies in the rapid response of the COVID-19 pandemic: a systematic review (2021) (36)
Detection of drug resistance associated mutations in HIV primary infection within the UK. (2000) (36)
Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017 (2017) (36)
Recombinant strains of HIV type 1 in the United Kingdom. (2001) (36)
Surveillance for CMV infection in orthotopic liver transplant recipients. (1992) (35)
Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. (2015) (35)
Antiviral drug resistance (1996) (35)
Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa (2016) (35)
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines (2020) (34)
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load (2010) (34)
Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care (2013) (34)
HIV phylogenetics (2007) (34)
Probable Vertical Transmission of SARS-CoV-2 Infection (2020) (34)
Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial (2015) (34)
Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters (2004) (34)
Management of paediatric HIV-1 resistance (2009) (34)
HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination. (2012) (34)
Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis (2017) (33)
HIV resistance and the developing world. (2007) (33)
Rapid roll out of SARS-CoV-2 antibody testing—a concern (2020) (33)
The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu‐Natal (South Africa) (2018) (32)
Preventing Unintended Pregnancy and HIV Transmission: Effects of the HIV Treatment Cascade on Contraceptive Use and Choice in Rural KwaZulu-Natal (2014) (31)
The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection (2013) (31)
Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings (2014) (31)
Determinants of time from HIV infection to linkage-to-care in rural KwaZulu-Natal, South Africa (2017) (31)
Increasing HIV-1 Drug Resistance Between 2010 and 2012 in Adults Participating in Population-Based HIV Surveillance in Rural KwaZulu-Natal, South Africa (2016) (31)
Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial (2018) (30)
Hare TRIM5α Restricts Divergent Retroviruses and Exhibits Significant Sequence Variation from Closely Related Lagomorpha TRIM5 Genes (2010) (30)
Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain. (2013) (30)
Ethical considerations in global HIV phylogenetic research. (2018) (30)
Evolution of Antiretroviral Phenotypic and Genotypic Drug Resistance in Antiretroviral-Naive HIV-1-Infected Children Treated with Abacavir/Lamivudine, Zidovudine/Lamivudine or Abacavir/Zidovudine, with or without Nelfinavir (The Penta 5 Trial) (2001) (30)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. (2012) (30)
HIV‐1 Protease inhibitors: Their development, mechanism of action and clinical potential (1995) (30)
High HIV incidence and low uptake of HIV prevention services: The context of risk for young male adults prior to DREAMS in rural KwaZulu-Natal, South Africa (2018) (29)
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy (2015) (29)
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? (2008) (29)
Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. (2000) (29)
Investigation of HIV-1 transmission events by phylogenetic methods: requirement for scientific rigour. (2005) (29)
Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance (1998) (29)
A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study (2018) (28)
The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. (2013) (28)
Cervicovaginal HIV-1 Shedding in Women Taking Antiretroviral Therapy in Burkina Faso: A Longitudinal Study (2014) (27)
Respiratory viruses in adult liver transplant recipients. (1999) (27)
Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic (2016) (26)
The Impact of Different Definitions on the Estimated Rate of Transmitted HIV Drug Resistance in the United Kingdom (2008) (26)
Time and money: the true costs of health care utilization for patients receiving 'free' HIV/TB care and treatment in rural KwaZulu-Natal. (2015) (26)
Characterization of HIV type 1 clades in the Caribbean using pol gene sequences. (2003) (26)
High Prevalence of Hepatitis G Virus in Bone Marrow Transplant Recipients and Patients Treated for Acute Leukemia (1997) (26)
Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring (2010) (26)
No Evidence of XMRV or Related Retroviruses in a London HIV-1-Positive Patient Cohort (2011) (26)
Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study (2017) (26)
Value of routine surveillance cultures for detection of CMV pneumonitis following bone marrow transplantation. (1993) (25)
BK virus-associated haemorrhagic cystitis in an HIV-infected man. (1994) (25)
Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine (2010) (24)
Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1 (2011) (24)
Management of herpes virus infections following transplantation. (2000) (24)
The frequency of HIV-I drug resistance mutations among treatment-naïve individuals at a tertiary care centre in south India (2009) (24)
Audit of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms. (1993) (24)
Do gifts increase consent to home-based HIV testing? A difference-in-differences study in rural KwaZulu-Natal, South Africa (2016) (23)
PANGEA-HIV 2: Phylogenetics And Networks for Generalised Epidemics in Africa (2019) (23)
Factors influencing lopinavir and atazanavir plasma concentration. (2010) (23)
Retention in Care Trajectories of HIV-Positive Individuals Participating in a Universal Test-and-Treat Program in Rural South Africa (ANRS 12249 TasP Trial) (2018) (23)
Ultra-rapid, sensitive and specific digital diagnosis of HIV with a dual-channel SAW biosensor in a pilot clinical study (2018) (23)
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. (2001) (22)
Deep learning of HIV field-based rapid tests (2021) (22)
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact (2016) (22)
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? (2008) (22)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom (2010) (21)
Analysis of HIV‐1 variation in blood and semen during treatment and treatment interruption (2002) (21)
Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. (2014) (21)
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK (2016) (21)
A Randomized Controlled Trial of the Value of Phenotypic Testing in Addition to Genotypic Testing for HIV Drug Resistance: Evaluation of Resistance Assays (ERA) Trial Investigators (2005) (21)
Failure to initiate HIV treatment in patients with high CD4 counts: evidence from demographic surveillance in rural South Africa (2018) (21)
Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological Studies of HIV (2014) (20)
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression (2016) (20)
A Randomized Controlled Trial of Genotypic HIV Drug Resistance Testing in HIV-1-Infected Children: The Pera (Penta 8) Trial (2006) (20)
HIV-1 Full-Genome Phylogenetics of Generalized Epidemics in Sub-Saharan Africa: Impact of Missing Nucleotide Characters in Next-Generation Sequences (2017) (20)
Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation. (2017) (20)
Secondary parvovirus B19 infection in an immunocompromised child. (1991) (20)
Primary HIV Infection, phylogenetics, and antiretroviral prevention. (2007) (20)
Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara) (2012) (19)
The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children (2015) (19)
The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy (2005) (19)
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I (2019) (18)
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception (2011) (18)
Diagnosis of cytomegalovirus infection: a review. (1992) (18)
Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance * (2011) (18)
The Effect of HIV and the Modifying Effect of Anti-Retroviral Therapy (ART) on Body Mass Index (BMI) and Blood Pressure Levels in Rural South Africa (2014) (18)
HIV Type-1 Drug Resistance in Treatment-Naive Patients Monitored Using Minority Species Assays: A Systematic Review and Meta-Analysis (2011) (18)
Tracking external introductions of HIV using phylodynamics reveals a major source of infections in rural KwaZulu-Natal, South Africa (2018) (18)
Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study (2017) (17)
Drug-Resistant HIV-1 in the Semen of Men Receiving Antiretroviral Therapy with Acute Sexually Transmitted Infections (2002) (17)
Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo (2015) (16)
Phylogenetic and Demographic Characterization of Directed HIV-1 Transmission Using Deep Sequences from High-Risk and General Population Cohorts/Groups in Uganda (2020) (16)
Nosocomial transmission of influenza: A retrospective cross‐sectional study using next generation sequencing at a hospital in England (2012‐2014) (2019) (16)
Antiviral prophylaxis and treatment (excluding HIV therapy). (2002) (16)
Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring (2012) (16)
Respiratory virus infections in immunocompromised patients. (1998) (16)
Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance (2016) (16)
Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. (2009) (16)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study (2013) (15)
The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains (2011) (15)
A high HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project (2017) (15)
The priorities for antiviral drug resistance surveillance and research. (2007) (15)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study (2013) (15)
Causes and Consequences of Incomplete HIV RNA Suppression in Clinical Trials (2009) (15)
Evaluating the extent of potential resistance to pre‐exposure prophylaxis within the UK HIV‐1‐infectious population of men who have sex with men (2012) (15)
Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy (2008) (15)
Chronic Kidney Disease Risk in African and Caribbean Populations With HIV (2018) (15)
Population Trends in the Prevalence and Patterns of Protease Resistance Related to Exposure to Unboosted and Boosted Protease Inhibitors (2008) (15)
British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2001) (15)
The impact of ART initiation on household food security over time. (2017) (15)
Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus-infected hemophilia patients. National Cancer Institute Multicenter Hemophilia Cohort Study Group. (1993) (15)
Longitudinal Trends in the Prevalence of Detectable HIV Viremia: Population-Based Evidence From Rural KwaZulu-Natal, South Africa (2018) (14)
Determinants of HIV drug resistance mutations in plasma virus after treatment interruption (2005) (14)
Clinical outcomes after first‐line HIV treatment failure in South Africa: the next cascade of care (2020) (14)
The Effect of Antiretroviral Treatment on Health Care Utilization in Rural South Africa: A Population-Based Cohort Study (2016) (14)
The Art of HIV Elimination: Past and Present Science. (2015) (14)
Transient Viral Load Increases in HIV-Infected Children in the UK and Ireland: What do They Mean? (2007) (13)
Positive and Negative drug Selection Pressures on the N348I Connection Domain Mutation: New Insights from in vivo Data (2010) (13)
Implementing universal HIV treatment in a high HIV prevalence and rural South African setting – Field experiences and recommendations of health care providers (2017) (13)
Development and application of a new measure of engagement in out‐patient HIV care (2016) (13)
Antiviral drug resistance (1996) (13)
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa (2017) (13)
Hepatitis B serological markers and plasma DNA concentrations (2017) (13)
No evidence for cross-contamination of dried blood spots excised using an office hole-punch for HIV-1 drug resistance genotyping. (2009) (13)
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa (2015) (13)
GBV‐C/HGV coinfection in HIV‐1‐positive men: Frequent detection of viral RNA in blood plasma but absence from seminal fluid plasma (1998) (12)
Potential impact of early antiretroviral therapy on transmission (2009) (12)
Impact of early antiretroviral therapy eligibility on HIV acquisition: household-level evidence from rural South Africa (2018) (11)
HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy (2007) (11)
Emergence and evolution of drug resistance in the absence of viral load monitoring during 48 weeks of Combivir/Tenofovir within the DART Trial. (2007) (11)
Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. (2019) (11)
Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions (2003) (11)
Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy. (1999) (11)
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART (2018) (11)
A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing (2021) (11)
Sources of social support and sexual behaviour advice for young adults in rural South Africa (2018) (11)
Computer-aided interpretation of chest radiography reveals the spectrum of tuberculosis in rural South Africa (2021) (11)
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations (2017) (11)
Dark matter, second waves and epidemiological modelling (2020) (11)
Combination antiretroviral therapy and cell–cell spread of wild-type and drug-resistant human immunodeficiency virus-1 (2017) (10)
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom (2016) (10)
The effect of highly active antiretroviral therapy for HIV on the anti‐HCV specific humoral immune response (2004) (10)
Phylodynamic and phylogeographic patterns of the HIV type 1 subtype F1 parenteral epidemic in Romania. (2012) (10)
The impact of self-interviews on response patterns for sensitive topics: a randomized trial of electronic delivery methods for a sexual behaviour questionnaire in rural South Africa (2017) (10)
Implications for HIV testing policy derived from combining data on voluntary confidential testing with viral sequences and serological analyses (2008) (10)
Prospective cytomegalovirus surveillance in paediatric renal transplant patients (1993) (10)
List randomization for eliciting HIV status and sexual behaviors in rural KwaZulu-Natal, South Africa: a randomized experiment using known true values for validation (2018) (10)
BMI and All‐Cause Mortality in a Population‐Based Cohort in Rural South Africa (2020) (10)
Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B virus, and HIV. (1998) (10)
Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa (2010) (10)
The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk (2012) (10)
Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa (2018) (10)
The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns. (2010) (10)
Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up (2012) (10)
Genital herpes, "the new paradigm". (1999) (10)
High prevalence of hepatitis G virus in bone marrow transplant recipients and patients treated for acute leukemia. (1997) (9)
Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies (2006) (9)
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance (2012) (9)
“They have this not care – don’t care attitude:” A Mixed Methods Study Evaluating Community Readiness for Oral PrEP in Adolescent Girls and Young Women in a Rural Area of South Africa (2020) (9)
HIV drug resistance: genotypic assays and their possible applications. (1998) (9)
Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network (2013) (9)
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project (2016) (9)
Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus (1999) (9)
Cytomegalovirus viral load testing of blood using quantitative polymerase chain reaction in acutely unwell HIV-1-positive patients lacks diagnostic utility (2007) (9)
The impact of lay counselors on HIV testing rates: quasi-experimental evidence from lay counselor redeployment in KwaZulu-Natal, South Africa (2018) (9)
High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial (2014) (9)
The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication. (2008) (8)
Linkage to primary care after home-based blood pressure screening in rural KwaZulu-Natal, South Africa: a population-based cohort study (2018) (8)
Population-Level Decline in BMI and Systolic Blood Pressure Following Mass HIV Treatment: Evidence from Rural KwaZulu-Natal (2016) (8)
Pervasive and non-random recombination in near full-length HIV genomes from Uganda (2020) (8)
Hepatitis G virus infection in patients with bleeding disorders (1997) (8)
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation (2015) (8)
A long-term follow-up of hepatitis B vaccination in patients with congenital clotting disorders. (1994) (8)
UK HIV drug resistance database: background and recent outputs. (2007) (8)
Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy (2015) (8)
CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus (2017) (8)
Aciclovir resistance among Indian strains of Herpes simplex virus as determined using a dye uptake assay. (2007) (8)
Antiretroviral therapy based HIV prevention targeting young women who sell sex: a mixed method approach to understand the implementation of PrEP in a rural area of KwaZulu-Natal, South Africa (2021) (7)
Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction (2018) (7)
From the micro to the macro to improve health: microorganism ecology and society in teaching infectious disease epidemiology (2020) (7)
Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy (2015) (7)
Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. (2005) (7)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. (2009) (7)
‘Dark matter’, second waves and epidemiological modelling (2020) (7)
An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs (2017) (7)
HIV viral load: the myth of the undetectable? (2002) (7)
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women (2012) (7)
Quantifying the contribution of different aged men and women to onwards transmission of HIV-1 in generalised epidemics in sub-Saharan Africa: A modelling and phylogenetics approach from the HPTN071 (PopART) trial (2019) (7)
Characterization of CMVpp65-Specific CD81 T Lymphocytes Using MHC Tetramers in Kidney Transplant Patients and Healthy Participants. Transplantation 2000; 69: 2243. (2000) (7)
Gender factors influencing participation in the elimination of mother-to-child transmission of HIV program in Uganda under Option B+. (2017) (7)
Sociobehavioral and community predictors of unsuppressed HIV viral load: multilevel results from a hyperendemic rural South African population (2019) (7)
Predictive value of the ultrasensitive HIV viral load assay in clinical practice (2000) (7)
The impact of continuous quality improvement on coverage of antenatal HIV care tests in rural South Africa: Results of a stepped-wedge cluster-randomised controlled implementation trial (2020) (7)
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? (2012) (7)
Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1. (2001) (7)
Risk factors for viral reactivation following bone marrow transplantation (2005) (7)
HIV-1 integrase sequence variation and covariation (2007) (6)
Book review. Antiviral Drug Resistance Ed. by Douglas D. Richman, John Wiley & Sons, Chichester, 1996. (1998) (6)
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent (2004) (6)
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV (2019) (6)
Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection (2010) (6)
844. Engagement in HIV Care as an Avenue to Primary Care in Rural South Africa: Results from the Vukuzazi Population Health Platform (2019) (6)
Effective immunity and second waves: a dynamic causal modelling study. (2020) (6)
The Role of Phylogenetics as a Tool to Predict the Spread of Resistance (2017) (6)
Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study (2009) (6)
Cohort Profile: The Vukuzazi (‘Wake Up and Know Yourself’ in isiZulu) population science programme (2021) (6)
Single-centre experience of allogeneic haemopoietic stem cell transplant in paediatric patients in Cape Town, South Africa. (2017) (6)
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance (2018) (6)
Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa (2019) (6)
Computer-aided interpretation of chest radiography to detect TB in rural South Africa (2020) (6)
The MONARCH intervention to enhance the quality of antenatal and postnatal primary health services in rural South Africa: protocol for a stepped-wedge cluster-randomised controlled trial (2018) (6)
Updated BHIVA-BASHH Position Statement on PrEP in the UK (2015) (5)
The impact of HIV-1 subtype on drug resistance. (2001) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
External introductions helped drive and sustain the high incidence of HIV-1 in rural KwaZulu-Natal, South Africa (2017) (5)
Antiviral Drug Resistance: From the Laboratory to the Patient (1998) (5)
No effect of test and treat on sexual behaviours at population level in rural South Africa (2019) (5)
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women (2014) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
HIV virology, testing and monitoring (2013) (5)
Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa (2021) (5)
Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score (2011) (5)
Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women? (2014) (5)
Hepatitis G virus (HGV) and lymphoproliferative disorders. (1997) (5)
The prevalence of reduced zidovudine susceptibility in zidovudine‐naive, antiretroviral‐experienced HIV‐1‐infected patients (2003) (5)
The impact of structural and functional constraints acting at the nucleic acid level on the evolution of drug resistance in HIV-1 (2006) (5)
CD4+ T-Cell Count at Antiretroviral Therapy Initiation in the “Treat-All” Era in Rural South Africa: An Interrupted Time Series Analysis (2021) (5)
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data (2017) (4)
Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control (2016) (4)
Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. (2016) (4)
“If you are here at the clinic, you do not know how many people need help in the community”: Perspectives of home-based HIV services from health care workers in rural KwaZulu-Natal, South Africa in the era of universal test-and-treat (2018) (4)
O112 Trends in transmitted HIV drug resistance among non-B subtypes in the UK (2008) (4)
Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection. (2003) (4)
Open science communication: The first year of the UK's Independent Scientific Advisory Group for Emergencies (2022) (4)
Socio-behavioural and community predictors of unsuppressed viral load: multi-level results from a hyper-endemic rural South African population. (2019) (4)
Pooled specimens for HIV RNA monitoring: cheaper, but is it reliable? (2014) (4)
Early ART Initiation Improves HIV Status Disclosure and Social Support in People Living with HIV, Linked to Care Within a Universal Test and Treat Program in Rural South Africa (ANRS 12249 TasP Trial) (2020) (4)
The Association between Detected drug Resistance Mutations and CD4+ T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen (2018) (3)
Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes (2003) (3)
Limitations of proposed novel trial design. (2012) (3)
Emergence of drug resistance in hiv-1 infected patients after first-line highly active antiretroviral therapy (haart): a systematic review of clinical trials (2008) (3)
Does antiretroviral therapy use affect the accuracy of HIV rapid diagnostic assays? Experience from a demographic health and surveillance site in rural South Africa☆☆☆ (2020) (3)
Exploring plasma-virus-derived gag-protease interrelationships in drug resistance and fitness landscape (2007) (3)
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
Effective immunity and second waves: a dynamic causal modelling study (2020) (3)
Antiretroviral drug resistance (2011) (3)
Taking connected mobile-health diagnostics of infectious diseases to the field (2019) (3)
A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada (2017) (3)
Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda (2014) (3)
P407 ‘MTV shuga’: mass media communication, HSV2 and sexual health in adolescent girls and young women in rural south africa (2019) (3)
HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy (2021) (2)
ARHAI: antiviral resistance. (2012) (2)
Improving the Validity of Mathematical Models for HIV Elimination by Incorporating Empirical Estimates of Progression Through the HIV Treatment Cascade (2018) (2)
Mapping nevirapine and efavirenz resistance using Bayesian networks of HIV-1 pol sequences of subtypes A, B, C, F and G (2005) (2)
Synonomous genetic changes within subtype FHIV-1 may influence mutational routes to drug resistance (2003) (2)
A Continuous Quality Improvement Intervention to Improve Antenatal HIV Care Testing in Rural South Africa: Evaluation of Implementation in a Real-World Setting (2020) (2)
A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance (2005) (2)
Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors (2015) (2)
Prevalence of drug resistance in untreated HIV-1-infected individuals in low- and middle-income countries: a systematic review and meta-analysis (2011) (2)
Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring (2011) (2)
Independent SAGE replies to The BMJ (2021) (2)
Genomic Characteristics and Clinical Impact of the Emergent SARS-CoV-2 B.1.1.7 Lineage in North Central London, November to December 2020 (2021) (2)
Working Party Report Management of herpes virus infections following transplantation A Report from the British Society for Antimicrobial Chemotherapy Working Party* on Antiviral Therapy (2000) (2)
What is the drug resistance mutational infectious burden in an HIV-1 prevalent cohort and the relationship to incidence of transmitted resistance? (2006) (2)
Interactions between nevirapine resistance mutations and NRTI resistance mutations (2005) (2)
Hepatic Dysfunction in a Population of Antibody–Deficient Patients: Prevalence, Aetiology and Outcome of PCR Screening for Hepatitis C and G Viruses (1999) (2)
Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting. (2010) (2)
Caring for a patient with rabies: implications of the Milwaukee protocol for infection control and public health measures. (2017) (2)
Entry into care following universal home-based HIV testing in rural KwaZulu-Natal, South Africa : the ANRS TasP 12249 cluster-randomized trial (2015) (2)
Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes (2005) (2)
The impact of transmitted drug resistance on time to CD4 < 350 cells/ml (2002) (2)
HIV testing and monitoring (2001) (2)
Resistance tests: what do clinical trials tell us? (2002) (2)
Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance (2019) (2)
Pitfalls of Single Measurement Screening for Diabetes and Hypertension in Community-Based Settings (2021) (2)
Cytomegalovirus excretion after bone marrow transplantation cannot be predicted from the pre‐transplant level of IgG antibodies (1991) (2)
Development of a novel application for visualising infectious diseases in hospital settings (2017) (2)
Prevalence and in vitro characteristics of reverse transcriptase (RT) N348I mutation in non-B subtypes, in the absence of viral load monitoring, in the DART Study (NORA substudy). (2009) (2)
Selection of resistance following first-line anti-retroviral regimens among HIV-1 subtypes (2005) (2)
Monitoring of antiretroviral therapy in low-resource settings – Authors' reply (2008) (2)
Body mass index and all-cause mortality in a population-based cohort in rural South Africa (2020) (1)
Incidence of transmitted anti-retroviral drug resistant HIV may be rising in the UK (2000) (1)
Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial (2016) (1)
P1 Assessing the role of treatment adherence in a clinical setting (2000) (1)
HIV Treatment Substantially Decreases Hospitalization Rates: Evidence From Rural South Africa. (2018) (1)
Pregnancies among women seen for HIV-clinical care - predictors and trends over time (2012) (1)
Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system (2007) (1)
Genomesand Assembly of HIV-1 Universal Amplification, Next-Generation (2014) (1)
O111 Global impact of HIV drug resistance (2008) (1)
Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)) (2002) (1)
O14.6 Mafrica: zenzele, a mobile-phone enabled HIV testing and linkage to care pathway for young people in rural south africa (2019) (1)
Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness (2021) (1)
Correction to: Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa (2022) (1)
Influence of subtype and treatment on genetic profiles of HIV-1 reverse transcriptase and protease: do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences? (2002) (1)
Bayesian graphical models in the analysis of HIV drug resistance data from the UK HIV Drug Resistance Database (2006) (1)
Pilot scheme for performance assessment of HIV-1 genotypic resistance testing in the UK. (2004) (1)
Emergence of drug resistance after failure of first-line HAART is associated with intensity of virological monitoring: a systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy (2008) (1)
immunocompetent girl (2007) (1)
Antiretroviral resistance in the developing world. (2007) (1)
Audit of HIV RNA quantitation measurements in the West Midlands: a preliminary report (1998) (1)
Immediate HIV treatment prevents new infections: causal evidence on the real- world impact of immediate versus deferred ART in rural South Africa (2016) (1)
Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection. Glasgow, United Kingdom. November 7-11, 2010. (2010) (1)
Universal Test and Treat and the HIV epidemic in rural South Africa ; a community cluster randomized trial (2017) (1)
Costs and economies of scale in repeated home-based HIV counselling and testing: Evidence from the ANRS 12249 Treatment as Prevention trial in South Africa (2022) (1)
Assessment of viral diversity during viral rebound in a HIV-1 elite controller (2014) (1)
Principles of virology (2009) (1)
HIV diagnosis and antiretroviral therapy (2008) (1)
Differences in the dynamics of viral rebound and evolution of resistance between CBV/NVP and CBV/ABC (NORA sub study of DART trial) uncovered in the absence of viral load monitoring in real time. (2008) (1)
Disappointments in the treatment of acute viral infections: what's the problem? (2002) (1)
Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells (2013) (1)
Detection of cytomegalovirus by a rapid culture system: a comparison of monoclonal antibodies in a clinical setting. (1992) (1)
Identification of HIV-1 matrix determinants of fitness compensation in a protease inhibitor resistant virus (2009) (1)
Disability for HIV and Disincentives for Health: The Impact of South Africa's Disability Grant on HIV/AIDS Recovery (2018) (1)
Long-term probability of detecting HIV drug resistance in drug-naïve patients starting currently recommended first-line combination ART. (2008) (1)
The Human Retroviruses, Robert C. Gallo, Gilbert Jay (Eds.). Academic Press, New York (1991), 421 (1993) (1)
ANTIVIRAL DRUGS : FROM DEVELOPMENT TO RESISTANCE (1998) (1)
Viral reactivation and immune reconstitution following Campath 1H and fludarabine based non-myeloablative conditioning for allogeneic stem cell transplantation compared to Campath-based T cell depletion regimens: A preliminary report. (1999) (1)
Go local: The key to controlling the COVID-19 pandemic in the post lockdown era (2020) (1)
UpdateoftheDrugResistanceMutationsinHIV-1: Spring 2008 (2008) (1)
Decision letter: Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19 (2020) (1)
HIV Infection in a Long-Term Renal Transplant Recipient (1995) (1)
The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk (2012) (1)
learning of HIV field-based rapid tests’ (2021) (1)
The potential role of minority mutation assays in surveillance of transmitted drug resistance (2009) (1)
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. (2021) (1)
Measurement of nucleoside analogue triphosphates by enzymatic assay in HIV patients in a clinical setting (2000) (0)
Phenotypic data to guide selection of reverse transcriptase inhibitors in second-line therapy following extended virological failure in Uganda (2009) (0)
Viral Infections, Contemporary Issues in Infectious Diseases. K. Root Richard & E. Sande Merle. Pp. 218+20 figs. Edinburgh: Churchill Livingstone; 1992. (1993) (0)
What's New (1988) (0)
Additive Antiviral Effects of Lamivudine and α-Interferon in Chronic Hepatitis B Infection (1999) (0)
Effectiveness of the dolutegravir transition in Uganda: Disco cohort week-24 results (2021) (0)
O10.2 Impact of HIV-PrEP for female sex workers on community-wide awareness, uptake, and perceptions in a rural-area kwazulu-natal (2019) (0)
1 Ethical Considerations in Global HIV Phylogenetic Research (2018) (0)
Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis (2019) (0)
Reply to Ambrosioni et al. (2018) (0)
Reply to Cohen et al. (2016) (0)
Dynamics of accumulation of drug resistance mutations in the absence of virological monitoring in HIV-1-infected Zambian children using adult Triomune (fixed-dose combination d4T, 3TC and NVP) (2009) (0)
South Africa - Vukuzazi Machine Learning Chest X-ray project among individuals aged 15 years and above in rural KwaZulu Natal, South Africa, 2018 (2018) (0)
Seeing our world through the Life Sciences (2014) (0)
The drug susceptibility and viral fitness of recombinant viruses expressing patient-derived integrase genes are significantly affected by co-evolved multidrug-resistant protease and reverse transciptase genes (2013) (0)
Combination HIV prevention and the battle of the sexes (2015) (0)
Title Computer-aided interpretation of chest radiography to detect TB in rural South Africa (2020) (0)
Prevalence of atypical mutations at codon 215 of HIV-1 reverse transcriptase (2002) (0)
Transmitted HIV drug resistance: effect of treatment intensification in limiting the epidemic (2005) (0)
Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure (2014) (0)
P012 A process evaluation of an incentivized home-based intervention to test and start (HITS) in rural kwazulu-natal, south africa (2019) (0)
Infant feeding knowledge and practice vary by maternal HIV status: a nested cohort study in rural South Africa (2020) (0)
Resistance in the context of Mother-to-Child transmission Mother-to-child transmission of minority HIV-1 drug resistant strains (2005) (0)
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations initiating therapy : modelling study and economic analysis (2018) (0)
Viral Infections. Contemporary Issues in Infectious Diseases (1993) (0)
Erratum to “Antiviral prophylaxis and treatment (excluding HIV therapy)” (2003) (0)
Linkage to HIV care and hypertension and diabetes control in rural South Africa: Results from the population-based Vukuzazi Study (2022) (0)
AIDS therapy, 3rd edition, Dolin, Massur, Saag (Eds.). Churchill Livingstone, Elsevier (2008) (2008) (0)
Potent HBV therapy and availability of laboratory monitoring fail to abrogate increased risk of death in HBV-HIV-co-infected individuals in the DART study (2011) (0)
Meningitis and stridor in advanced Human immunodeficiency virus/acquired immune deficiency syndrome (2013) (0)
Implementation and effectiveness of a linkage to HIV care intervention in rural South Africa (ANRS 12249 TasP trial) (2023) (0)
It's not enough to test for HIV and treat it - social factors matter too : HIV and AIDS (2016) (0)
Maternal infections. Part 2: Cytomegalovirus. (1996) (0)
Imported HIV infection: the danger of stigmatisation (2017) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI (2011) (0)
Protease inhibitors are effective at inhibiting cell-to-cell HIV-1 transfer (2013) (0)
Complex genotypic changes during failure of HBV nucleoside analogue therapy (2003) (0)
Evidence for rising prevalence of HIV-1 drug resistance in primary infections in the UK (2001) (0)
Combination antiviral therapy: but which combination, and why? (2000) (0)
Management of HIV Drug-Resistant Infections (2004) (0)
CONCISE COMMUNICATION Resistance to Antiviral Drugs in Herpes Simplex Virus Infections among Allogeneic Stem Cell Transplant Recipients: Risk Factors and Prognostic Signiﬁcance (0)
Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing (2009) (0)
Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients (2002) (0)
Hepatic Dysfunction in a Population of Antibody‐Deficient Patients: Prevalence, Aetiology and Outcome of PCR Screening for Hepatitis C and G Viruses (1999) (0)
Identification of the phenotypic, genotypic and fitness correlates of non-B subtype HIV-1 NRTI resistance through longitudinal analysis of children with virological failure in the developing world (2010) (0)
P34 Failure of sequential nucleoside analogue monotherapy for the treatment of HBV in HIV/HBV co-infected patients (2000) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Different evolution of resistance uncovered by single-genome sequencing analysis of patients with long-term virological failure during continuous or interrupted antiretroviral therapy (2010) (0)
HHV-6 and HHV-7 in febrile convulsions of young children (1996) (0)
Towards an ultra-rapid smartphone- connected test for infectious diseases (2017) (0)
Antivirals Against AIDS R. E. Unger, J. Kreuter & H. Rubsamen-Waigmann. Marcel Dekker, Inc., New York, NY, 2000.ISBN 0-8427-0358-8. $150.00. (2001) (0)
Different evolution of resistance uncovered by single genome sequencing (SGS) analysis of patients with long term virological failure during continuous or interrupted therapy. (2010) (0)
Original articles 98 Seroprevalence and incidence of genital ulcer infections in a rural Ugandan (1999) (0)
Is nucleoside analogue monotherapy sufficient for treatment of HBV infection? Lessons from HIV. (1999) (0)
Leader Genital herpes , “ the new paradigm ” (1998) (0)
Genome-wide association study of HIV whole genome sequences validated using drug 1 resistance 2 (2016) (0)
What aff ects the decisions of parents to allow their infant to participate in a therapeutic vaccine trial ? • What enrolment criteria and endpoints should be considered in a therapeutic vaccine trial that targets paediatric patients with HIV ? (2015) (0)
Implications for Europe of high prevalence of HIV drug resistance in the United States (2002) (0)
A Replication Plan for “Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomized trial” (2019) (0)
The HIV-1 protease mutation K55R is associated with the presence of the M461/L mutation (2003) (0)
P25 The relationship between ARV drug levels, drug resistance, adherence and treatment failure in a routine clinical setting (2000) (0)
Predicting the effects on resistance of lack of viral load monitoring in resource-limited settings (2008) (0)
What's New (2000) (0)
industrial and developing countries with the shared goal of ending the HIV/AIDS pandemic. (2015) (0)
Antiretroviral Therapy Based Hiv Prevention Targeting Young Female-Sex Workers: A Mixed Method Approach to Understand the Implementation of Prep in a Rural Area of Kwazulu-Natal, South Africa (2020) (0)
Transacting Functions of Human Retroviruses (1996) (0)
Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virologic suppression (2017) (0)
Control of bloodborne viral infections (2009) (0)
HIV Transmission Dynamics (2016) (0)
Hu, J. et al. (2018) The impact of lay counselors on HIV testing rates: quasi-experimental evidence from lay counselor redeployment in KwaZulu- (2019) (0)
The prevalence of hepatitis G virus in high risk patient groups (1997) (0)
Virus induced enzymes, J. M. Morrison, John Wiley and Sons, Chichester (1991). Hardback, 655 pp. £85.00; $180.85. ISBN 0471 923 397. (1992) (0)
O5 Genotypic drug‐resistance testing in early HIV infection (2000) (0)
What's New (2002) (0)
Estimation of virological residual activity on a regimen of abacavir/zidovudine/lamivudine (ABC/3TC/ZDV). (2010) (0)
Multidrug resistant HIV and rapid progression of disease reported from New York. (2005) (0)
Towards an ultra-rapidsmartphone- connected test forinfectious diseases (2017) (0)
Virological and clinical outcomes in patients with multi (three)-class drug resistant (MDR) HIV in the UK. (2005) (0)
Publisher Correction: Computer-aided interpretation of chest radiography reveals the spectrum of tuberculosis in rural South Africa (2021) (0)
Antiviral drug resistance. (1998) (0)
Combination Antiretroviral Therapy (cART) and Cell-cell spread of Wild-type and Drug-Resistant HIV-1 (2017) (0)

This paper list is powered by the following services:

Other Resources About Deenan Pillay

iris.ucl.ac.uk

What Schools Are Affiliated With Deenan Pillay?

Deenan Pillay is affiliated with the following schools:

Deenan Pillay's Academic­Influence.com Rankings

Deenan Pillay's Degrees

Why Is Deenan Pillay Influential?

Deenan Pillay's Published Works

Published Works

Other Resources About Deenan Pillay

What Schools Are Affiliated With Deenan Pillay?

Deenan Pillay's AcademicInfluence.com Rankings